Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: Assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy

Bone

Volumn 34, Issue 3, 2004, Pages 539-546

  Arikoski, Pekka ^a,b   Silverwood, Brian ^a   Tillmann, Vallo ^a   Bishop, Nicholas J ^a,c  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Bone growth; Bone mass; Children; Osteogenesis imperfecta; Pamidronate

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; PAMIDRONIC ACID;

ADOLESCENT; ARTICLE; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; HUMAN; LUMBAR VERTEBRA; MALE; OSTEOGENESIS IMPERFECTA; SKELETON; TREATMENT OUTCOME;

ADOLESCENT; BIOLOGICAL MARKERS; BONE AND BONES; CHILD; CHILD, PRESCHOOL; DENSITOMETRY, X-RAY; DIPHOSPHONATES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; OSTEOGENESIS IMPERFECTA; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 1542346303     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2003.11.019     Document Type: Article

References (23)

1. Albright J.A., Grunt J.A. Studies of patients with osteogenesis imperfecta. J. Bone Jt. Surg., Am. 53:1971;1415-1425.
2. Åström E., Söderhäll S. Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch. Dis. Child. 86:2002;356-364.
3. Åström E., Söderhäll S. Beneficial effect of bisphosphonate during five years of treatment in children with severe osteogenesis imperfecta. Acta Paediatr. 87:1998;64-68.
4. Castells S. New approaches to treatment of osteogenesis imperfecta. Clin. Orthop. 93:1973;239-249.
5. Cattell H.S., Clayton B. Failure of anabolic steroids in the therapy of osteogenesis imperfecta: a clinical, metabolic, and biochemical study. J. Bone Jt. Surg., Am. 50:1968;123-141.
6. Duncan C.S., Blimkie C.J., Cowell C.T., Burke S.T., Briody J.N., Howman-Giles R. Bone mineral density in adolescent female athletes: relationship to exercise type and muscle strength. Med. Sci. Sports Exerc. 34:2002;286-294.
7. Glorieux F.H., Ward L.M., Rauch F., Lalic L., Roughley P.J., Travers R. Osteogenesis imperfecta type VI: a form of brittle bone disease with a mineralization defect. J. Bone Miner. Res. 17:2002;30-38.
8. Glorieux F.H., Rauch F., Plotkin H., Ward L., Travers R., Roughley P.et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J. Bone Miner. Res. 15:2000;1650-1658.
9. Glorieux F.H., Bishop N.J., Plotkin H., Chabot G., Lanoue G., Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N. Engl. J. Med. 339:1998;947-952.
10. Heinonen A., Sievänen H., Kannus P., Oja P., Vuori I. Site-specific skeletal response to long-term weight training seems to be attributable to principal loading modality: a pQTC study of female weightlifters. Calcif. Tissue Int. 70:2002;469-474.
11. Hillam R.A., Jackson M., Goodship A.E., Skerry T.M. Regional differences in human bone strain in vivo. J. Bone Miner. Res. 10:1995;S443.
12. Landsmeer-Beker E.A., Massa G.G., Maaswinkel-Mooy P.E., van de Kamp J.J., Papapoulos S.E. Treatment of osteogenesis imperfecta with bisphosphonate olpandronate (dimethylaminohydroxypropylidene bisphosphonate). Eur. J. Pediatr. 156:1997;972-974.
13. Pedersen U., Charles P., Hansen H.H., Elbrond O. Lack of effects of human calcitonin in osteogenesis imperfecta. Acta Orthop. Scand. 56:1985;260-264.
14. Plotkin H., Rauch F., Bishop N., Montpetit K., Ruck-Gibis J., Travers R.et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J. Clin. Endocrinol. Metab. 85:2000;1846-1850.
15. Robling A.G., Hinant F.M., Burr D.B., Turner C.H. Improved bone structure and strength after long-term mechanical loading is greatest if loading is separated into short bouts. J. Bone Miner. Res. 17:2002;1545-1554.
16. Schoenau E., Neu C.M., Beck B., Manz F., Rauch F. Bone mineral content per muscle cross-sectional area as an index of the functional muscle-bone unit. J. Bone Miner. Res. 2002;1095-1101.
17. Schoenau E., Neu C.M., Rauch F., Manz F. The development of bone strength at the proximal radius during childhood and adolescence. J. Clin. Endocrinol. Metab. 86:2001;613-618.
18. Schoenau E., Neu C.M., Mokov E., Wassmer G., Manz F. Influence of puberty on muscle area and cortical bone area of the forearm in boys and girls. J. Clin. Endocrinol. Metab. 85:2000;1095-1098.
19. Sillence D.O. Osteogenesis imperfecta nosology and genetics. Ann. N.Y. Acad. Sci. 543:1988;1-15.
20. Sillence D.O., Senn A., Danks D.M. Genetic heterogeneity in osteogenesis imperfecta. J. Med. Genet. 16:1979;101-116.
21. Ward L.M., Rauch F., Travers R., Chabot G., Azouz E.M., Lalic L.et al. Osteogenesis imperfecta type VII: an autosomal recessive form of brittle bone disease. Bone. 31:2002;12-18.
22. Widmann R.F., Bitan F.D., Laplaza F.J., Burke S.W., DiMaio M.F., Schneider R. Spinal deformity, pulmonary compromise, and quality of life in osteogenesis imperfecta. Spine. 24:1999;1673-1678.
23. Lee Y.S., Low S.L., Lim L.A., Loke K.Y. Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta. Eur. J. Pediatr. 160:2001;641-644.